Welcome to our dedicated page for Merus news (Ticker: MRUS), a resource for investors and traders seeking the latest updates and insights on Merus stock.
Merus N.V. (MRUS) is a clinical-stage biotechnology company pioneering bispecific antibody therapeutics for cancer treatment through its Biclonics® platform. This page provides investors and researchers with centralized access to official announcements, clinical trial updates, and strategic developments shaping the company's trajectory in immuno-oncology.
Find timely updates on Merus' investigational therapies, including progress across multiple cancer indications. Track key milestones such as regulatory feedback, partnership expansions with pharmaceutical collaborators, and financial performance updates. Our aggregation ensures efficient monitoring of material events without promotional bias.
Content spans clinical data disclosures, research collaborations with industry leaders like Incyte and Lilly, intellectual property developments, and financial reporting. Each update is categorized for quick scanning while maintaining technical accuracy required for biotech analysis.
Bookmark this page for streamlined access to Merus' evolving story in multispecific antibody development. Combine our news repository with SEC filings and scientific publications for comprehensive investment research approach.
Merus N.V. (Nasdaq: MRUS), a company specializing in oncology and developing innovative multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), has announced upcoming presentations at two major investor conferences. CEO Bill Lundberg will present at the William Blair 45th Annual Growth Stock Conference on June 3 at 9:40 a.m. ET and the Jefferies Global Healthcare Conference on June 4 at 3:10 p.m. ET. The presentations will be available via webcast on the company's Investors page, with recordings accessible for a limited time afterward.
- 79% overall survival rate at 12 months - 9 months median progression-free survival - Responses observed across PD-L1 levels - 14 responding patients still on treatment
The treatment combination was generally well-tolerated, with Grade ≥3 treatment-emergent adverse events occurring in 60% of patients. Infusion-related reactions were reported in 38% of patients, mainly during first infusion. The data suggests potential superiority over pembrolizumab monotherapy, positioning petosemtamab as a possible future standard of care in head and neck cancer. Merus expects to share top-line interim readout of phase 3 trials in 2026.
Merus (Nasdaq: MRUS), a biotechnology company specializing in oncology and the development of multispecific antibodies (Biclonics® and Triclonics®), has announced its participation in the BofA Securities 2025 Health Care Conference. CEO Bill Lundberg will engage in a fireside chat on May 15, 2025, at 8:40 a.m. PT/11:40 a.m. ET. The presentation will be available via webcast on the company's Investors webpage, with a recording accessible for a limited time afterward.
Merus N.V. (Nasdaq: MRUS) announced the acceptance of an abstract for presentation at the 2025 ASCO Annual Meeting in Chicago. The presentation will feature updated interim clinical data from their phase 2 trial of petosemtamab with pembrolizumab as first-line treatment for PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).
The poster presentation will include data on the complete 45-patient dataset, building upon previously presented early clinical efficacy and safety data from ASCO 2024. According to CEO Bill Lundberg, petosemtamab shows potential as a first and best-in-class treatment for r/m HNSCC, demonstrating substantial clinical activity superior to historical controls across ORR, PFS, and OS metrics.
The presentation is scheduled for June 2, 2025, and Merus will host an investor conference call on May 22, 2025, to discuss the full data set.
Merus N.V. (Nasdaq: MRUS), a biotechnology company specializing in innovative multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.
The company's President and CEO, Bill Lundberg, M.D., will engage in a fireside chat on Tuesday, April 8, 2025, at 8:45 a.m. ET. Investors and interested parties can access the live webcast through the Investors section of the Merus website, where the presentation recording will remain available for a time following the event.
Merus (NASDAQ: MRUS) announced financial results and business updates for Q4 and full year 2024. Key highlights include the FDA approval of BIZENGRI® for NRG1+ pancreatic adenocarcinoma and NSCLC patients, and two Breakthrough Therapy designations for petosemtamab.
The company is advancing two Phase 3 trials for petosemtamab: LiGeR-HN1 (in combination with pembrolizumab for 1L PD-L1+ r/m HNSCC) and LiGeR-HN2 (monotherapy in 2/3L r/m HNSCC), both expected to be substantially enrolled by year-end 2025. Interim data showed a 67% response rate in 1L HNSCC combination therapy and 36% response rate in 2L+ monotherapy.
Financial position remains strong with $724.0 million in cash, cash equivalents and marketable securities as of December 31, 2024, expected to fund operations into 2028.
FAQ
What is the current stock price of Merus (MRUS)?
What is the market cap of Merus (MRUS)?
